Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Epistem expected to sign more partners as TB test gets European approval, says broker

Stem cell specialist Epistem is likely to sign more partners for its Genedrive diagnostic platform, after being granted a CE mark as an in-vitro diagnostic medical device, reckons broker Peel Hunt.
Epistem expected to sign more partners as TB test gets European approval, says broker

 

---Adds broker comment and share price---

Stem cell specialist Epistem (LON:EHP) is likely to sign more partners for its Genedrive diagnostic platform, after being granted a CE mark as an in-vitro diagnostic medical device, reckons broker Peel Hunt. 

The certification means the test, which is based on its core Genedrive diagnostic platform, can now be sold across the European Economic Area (EEA).

Epistem received the CE-IVD registration for its rapid molecular test for tuberculosis (TB), an infectious and potentially lethal disease, which affects the lungs and causes a chronic cough.

Peel Hunt Analyst Dr Paul Cuddon said: “Genedrive has overcome the first key hurdle, and looks well set to continue to expand the menu, sign more commercial partners and maximise returns from a truly disruptive diagnostics innovation.”

He added that the registration also enables Epistem’s ability to broaden the range of tests across infectious diseases and cancer, where Genedrive has the technical specifications to become a “class leading technology.”

He added: “Not only is Genedrive cheaper than peers, its technical specifications are better.”

Peel Hunt gives a ‘buy’ recommendation on the stock and target price of 515 pence.

City broker Daniel Stewart agrees also giving a ‘buy’ recommendation and 496 pence target.

Epistem is now preparing regulatory submissions for India ahead of its first molecular TB test including patient assessment for antibiotic resistance towards the end of this year.

India has the largest number of TB sufferers in the world with more than two million new cases each year.

Dr Cuddon said: “A low cost, fast point of care molecular test has the potential to make a significant commercial and clinical impact through breaking the chain of disease transmission in rural areas.”

Matthew Walls, Epistem’s chief executive said: "This is an important milestone for the company as we move towards our first significant revenue stream in the commercialisation of Genedrive."

The CE-IVD mark is the first successful registration of a test using Genedrive.

The Genedrive platform provides a 'Point of Care' test applicable to a wide range of viral, bacterial, fungal and somatic mutation disease areas in less than thirty minutes.

Genedrive will be targeted at providing 'gold standard' identification of Mycobacterium tuberculosis and antibiotic resistance testing and will be priced competitively, Epistem added. 

In addition to its Genedrive platform Epistem also works in the discovery and development of biomarkers, which are used to monitor the progress of drug treatments.

The share price was up 1 per cent to 404 pence.

 

 

View full EHP profile

Epistem Holdings Plc Timeline

Newswire
February 19 2016
Newswire
January 13 2016

Related Articles

Lab-(1).jpg
December 02 2015
Firm aims to expand regenerative medicine and in-vitro diagnostics business
knee_5672a90cad559.jpg
December 17 2015
Put simply, Tissue Regenix takes a tendon or cartilage – either from a human or from a pig – treats it and uses it to replace damaged tissue within the body.
stem-cells.jpg
February 25 2016
Early 2016 looks to be data-rich for stem cell group ReNeuron as it progresses its clinical portfolio on multiple fronts.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.